BGXX (Bright Green) FCF Margin %: 0.00% (As of Jun. 2024)


What is Bright Green FCF Margin %?

Bright Green BGXX -2.56% FCF Margin % is 0.00% as of Jun. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bright Green's Free Cash Flow for the three months ended in Jun. 2024 was $-0.88 Mil. Bright Green's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Bright Green's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Bright Green's current FCF Yield % is 0.00%.

The historical rank and industry rank for Bright Green's FCF Margin % or its related term are showing as below:


BGXX's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.51
* Ranked among companies with meaningful FCF Margin % only.

Bright Green FCF Margin % Related Terms

Bright Green FCF Margin % Historical Data

* Premium members only.

The historical data trend for Bright Green's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Green FCF Margin % Chart

Bright Green Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Margin %
0.00 0.00 0.00 0.00

Bright Green Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BGXX vs BFRI, AYTU, CRYM: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bright Green's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Green FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bright Green's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bright Green's FCF Margin % falls into.


Bright Green FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bright Green's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.99/0
= %

Bright Green's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.882/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Bright Green (BGXX) has a FCF Margin % of 0.00% as of Jun. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bright Green and its competitors.
Is Bright Green's FCF Margin % too high?
Bright Green's current FCF Margin % is 0.00%.
How does Bright Green's FCF Margin % compare to BFRI and AYTU?
Bright Green's FCF Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bright Green and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Green's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Green stock overvalued right now?
Bright Green (BGXX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bright Green (BGXX), the current FCF Margin % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Green Business Description

Address 1033 George Hanosh Boulevard, Grants, NM, USA, 87020
Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).